<?xml version="1.0" encoding="UTF-8"?>
<p>The mAbs mentioned above were used to modulate the immune response, but specific human monoclonal antibodies can also be used to neutralize SARS-CoV-2, for both treatment and prevention of COVID-19. Several neutralizing monoclonal antibodies against SARS-CoV and MERS-CoV have potential cross reactivity against SARS-CoV-2 [
 <xref rid="B212-ijms-21-05559" ref-type="bibr">212</xref>]. For example, recent studies showed that a monoclonal antibody (S309) derived from memory B cells from an individual convalescing from SARS-CoV infection are also capable of neutralizing SARS-CoV-2 [
 <xref rid="B213-ijms-21-05559" ref-type="bibr">213</xref>].
</p>
